
GNFT Stock Forecast & Price Target
GNFT Analyst Ratings
Bulls say
Genfit SA is advancing its strategic position in the biotechnology sector with the anticipated approvals of Iqirvo in key EU markets, potentially unlocking a €26.5 million milestone payment from Ipsen, contingent on pricing and reimbursement approvals. The positive outcomes from the pivotal Phase 3 ELATIVE trial, where Iqirvo met its primary composite endpoint, underscore the robustness of the clinical data supporting its marketing authorization for Primary Biliary Cholangitis (PBC). Additionally, a recent royalty financing agreement with HealthCare Royalty could provide up to €185 million in funding, enhancing Genfit's financial position and supporting ongoing development efforts in innovative medicines and diagnostic solutions.
Bears say
Genfit SA faces considerable risks related to the timely progress of its clinical and regulatory efforts, particularly concerning its lead product, Iqirvo, which is crucial for the company's growth. Delays in clinical and regulatory timelines, along with potential failures to secure necessary approvals in new markets, could significantly hinder the company’s market potential and revenue generation. Additionally, unforeseen challenges in the commercial landscape for Iqirvo may adversely impact Genfit's financial outlook and investor confidence.
This aggregate rating is based on analysts' research of Genfit - ADR and is not a guaranteed prediction by Public.com or investment advice.
GNFT Analyst Forecast & Price Prediction
Start investing in GNFT
Order type
Buy in
Order amount
Est. shares
0 shares